PEPTONIC MEDICAL AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.06 SEK | -.--% |
|
-.--% | +3.45% |
| Apr. 17 | Peptonic Medical Plans SEK61 Million Shares, Warrants Issue | MT |
| Apr. 15 | Peptonic Medical Secures US Patent for Vaginal Yeast Infections Treatment | MT |
Valuation
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 132.9 | 27.31 | 43.01 | 261.1 | 281.5 | 119.8 |
| Enterprise Value (EV) 1 | 120.7 | 20.32 | 42.15 | 225.1 | 242.2 | 109.6 |
| P/E ratio | -11.8 x | -2.11 x | -2.88 x | -10.7 x | -9.05 x | -1.63 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 360,972,670 x | 112,370,490 x | 59,218,202 x | 13,227,048 x | 3,785,190 x |
| EV / Revenue | - | 268,590,236 x | 110,110,583 x | 51,064,691 x | 11,379,940 x | 3,464,329 x |
| EV / EBITDA | -11.8 x | -1.58 x | -2.95 x | -9.56 x | -7.95 x | -2.21 x |
| EV / FCF | -6.77 x | -1.51 x | -3.31 x | -21 x | -10.5 x | -11.6 x |
| FCF Yield | -14.8% | -66% | -30.2% | -4.77% | -9.52% | -8.64% |
| Price to Book | 2.16 x | 0.46 x | 0.78 x | 3.05 x | 2.39 x | 2.3 x |
| Nbr of stocks (in thousands) | 20,603 | 43,014 | 86,029 | 138,128 | 162,912 | 191,640 |
| Reference price 2 | 6.450 | 0.6350 | 0.5000 | 1.890 | 1.728 | 0.6250 |
| Announcement Date | 3/7/17 | 3/7/18 | 4/18/19 | 4/21/20 | 4/15/21 | 4/22/22 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net sales | - | 0.0757 | 0.3828 | 4.408 | 21.28 | 31.64 |
| EBITDA 1 | -10.25 | -12.88 | -14.31 | -23.54 | -30.47 | -49.61 |
| EBIT 1 | -10.26 | -12.96 | -14.38 | -23.92 | -31.05 | -73.72 |
| Operating Margin | - | -17,129.17% | -3,756.98% | -542.65% | -145.91% | -232.96% |
| Earnings before Tax (EBT) 1 | -11.26 | -12.97 | -14.94 | -24.51 | -31.33 | -73.69 |
| Net income 1 | -11.26 | -12.97 | -14.94 | -24.51 | -31.09 | -73.69 |
| Net margin | - | -17,144.11% | -3,903.26% | -555.95% | -146.09% | -232.87% |
| EPS 2 | -0.5464 | -0.3016 | -0.1737 | -0.1774 | -0.1909 | -0.3845 |
| Free Cash Flow 1 | -17.84 | -13.42 | -12.74 | -10.73 | -23.06 | -9.474 |
| FCF margin | - | -17,732.01% | -3,329.27% | -243.4% | -108.36% | -29.94% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/7/17 | 3/7/18 | 4/18/19 | 4/21/20 | 4/15/21 | 4/22/22 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 12.1 | 6.99 | 0.87 | 35.9 | 39.3 | 10.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -17.8 | -13.4 | -12.7 | -10.7 | -23.1 | -9.47 |
| ROE (net income / shareholders' equity) | -17.4% | -21.4% | -26% | -34.8% | -30.6% | -86.8% |
| ROA (Net income/ Total Assets) | -9.02% | -12.2% | -13.4% | -18.6% | -17.1% | -42.3% |
| Assets 1 | 124.9 | 106.7 | 111.8 | 132 | 181.3 | 174.3 |
| Book Value Per Share 2 | 2.990 | 1.390 | 0.6400 | 0.6200 | 0.7200 | 0.2700 |
| Cash Flow per Share 2 | 0.5900 | 0.1600 | 0.1300 | 0.2600 | 0.2400 | 0.0500 |
| Capex | - | - | - | - | - | 3.02 |
| Capex / Sales | - | - | - | - | - | 9.56% |
| Announcement Date | 3/7/17 | 3/7/18 | 4/18/19 | 4/21/20 | 4/15/21 | 4/22/22 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +3.45% | 8.4M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- PMED Stock
- Financials PEPTONIC medical AB
